Tenofovir Amibufenamide not checked
Hansoh · HS-10234
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Once-daily oral dose of 25 mg TMF were maintained in all participants”In the company’s words, NCT06743438 on ClinicalTrials.gov
- Tested for
- Hepatitis B, Chronic
- Main trialPhase 4
- “Tenofovir amibufenamide (TMF) is a novel prodrug of tenofovir that has been widely used in mainland China for the treatment of chronic hepatitis B (CHB). The previous registrational study (NCT03903796) has established the non-inferior virologic efficacy of TMF to tenofovir disoproxil fumarate (TDF), while demonstrating higher rates of alanine aminotransferase (ALT) normalization and improved bone and renal safety profiles. This study presented the long-term efficacy and safety of TMF in a phase IV study.”In the company’s words, NCT06743438 on ClinicalTrials.gov
- Other names
- HS-10234
Other drugs for Hepatitis B, Chronic
- GST-HG141Fujian Akeylink Biotechnology Co., Ltd. · Phase 3
- AHB-137Ausper Biopharma Co., Ltd. · Phase 3
- ZM-H1505RShanghai Zhimeng Biopharma, Inc. · Phase 3
- TQA3605Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3
- Tenofovir DFGilead (Kite) · Phase 3
- HT-101Suzhou HepaThera Biotech Co., Ltd. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Active, not recruiting | 30 Jun 2024 | Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB | |
| Phase 3Completed | 31 May 2020 | Study of the Efficacy and Safety of HS-10234 in Patients With Chronic Hepatitis B Virus Infection |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026